Key facts
- Notable investors include Big Sur Ventures, Science Creates.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tolemy Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Tolemy Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tolemy Bio
Operator of a biotechnology company intended to program cell metabolism for biomanufacturing. The company's technology uses metabolic modeling and minimal data to create uniquely designed cell culture media and offers solutions like cell-line and process data generation, model-driven prediction of cell culture media, and small-batch custom media manufacture, enabling researchers to efficiently manufacture advanced therapies through bespoke media design.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2024
- Employees
- 4
- Website
- tolemy.bio/
- Ownership
- Privately Held (backing)
Tolemy Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tolemy Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tolemy Bio in its N-PORT filings yet. We sweep new filings monthly.